These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 24121170)

  • 21. Evaluation of Ki-67 index in EUS-FNA specimens for the assessment of malignancy risk in pancreatic neuroendocrine tumors.
    Hasegawa T; Yamao K; Hijioka S; Bhatia V; Mizuno N; Hara K; Imaoka H; Niwa Y; Tajika M; Kondo S; Tanaka T; Shimizu Y; Kinoshita T; Kohsaki T; Nishimori I; Iwasaki S; Saibara T; Hosoda W; Yatabe Y
    Endoscopy; 2014 Jan; 46(1):32-8. PubMed ID: 24218309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pancreatic Neuroendocrine Tumors.
    Salaria SN; Shi C
    Surg Pathol Clin; 2016 Dec; 9(4):595-617. PubMed ID: 27926362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Re-evaluation of cases with gastroenteropancreatic neuroendocrine tumors between 2004 and 2012 according to the 2010 criteria.
    Ozkara S; Aker F; Yesil A; Senates E; Canbey C; Yitik A; Gonen C
    Hepatogastroenterology; 2013 Oct; 60(127):1665-72. PubMed ID: 24627925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of Ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease.
    Miller HC; Drymousis P; Flora R; Goldin R; Spalding D; Frilling A
    World J Surg; 2014 Jun; 38(6):1353-61. PubMed ID: 24493070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reliability of Ki-67 Determination in FNA Samples for Grading Pancreatic Neuroendocrine Tumors.
    Díaz Del Arco C; Díaz Pérez JÁ; Ortega Medina L; Sastre Valera J; Fernández Aceñero MJ
    Endocr Pathol; 2016 Dec; 27(4):276-283. PubMed ID: 27688080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67.
    Genç CG; Falconi M; Partelli S; Muffatti F; van Eeden S; Doglioni C; Klümpen HJ; van Eijck CHJ; Nieveen van Dijkum EJM
    Ann Surg Oncol; 2018 Aug; 25(8):2467-2474. PubMed ID: 29789972
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Morphologic Variants of Pancreatic Neuroendocrine Tumors: Clinicopathologic Analysis and Prognostic Stratification.
    Xue Y; Reid MD; Pehlivanoglu B; Obeng RC; Jiang H; Memis B; Lui SK; Sarmiento J; Kooby D; Maithel SK; El-Rayes B; Basturk O; Adsay V
    Endocr Pathol; 2020 Sep; 31(3):239-253. PubMed ID: 32488621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of WHO Classifications (2004, 2010), the Hochwald grading system, and AJCC and ENETS staging systems in predicting prognosis in locoregional well-differentiated pancreatic neuroendocrine tumors.
    Liu TC; Hamilton N; Hawkins W; Gao F; Cao D
    Am J Surg Pathol; 2013 Jun; 37(6):853-9. PubMed ID: 23598967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The relationship between MIB-1 proliferation index and outcome in pancreatic neuroendocrine tumors.
    Gentil Perret A; Mosnier JF; Buono JP; Berthelot P; Chipponi J; Balique JG; Cuilleret J; Dechelotte P; Boucheron S
    Am J Clin Pathol; 1998 Mar; 109(3):286-93. PubMed ID: 9495200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Should Ki67 immunohistochemistry be performed on all lesions in multifocal small intestinal neuroendocrine tumours?
    Numbere N; Huber AR; Shi C; Cates JMM; Gonzalez RS
    Histopathology; 2019 Feb; 74(3):424-429. PubMed ID: 30326145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic features of gastro-entero-pancreatic neuroendocrine neoplasms in primary and metastatic sites: Grade, mesenteric tumour deposits and emerging novelties.
    Kankava K; Maisonneuve P; Mangogna A; Centonze G; Cattaneo L; Prinzi N; Pusceddu S; Fazio N; Pisa E; Di Domenico S; Bertani E; Mazzaferro V; Albertelli M; Grillo F; Milione M
    J Neuroendocrinol; 2021 Aug; 33(8):e13000. PubMed ID: 34268808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Grade Assignment by Ki-67 Proliferative Index, Mitotic Count, and Phosphohistone H3 Count in Surgically Resected Gastrointestinal and Pancreatic Neuroendocrine Tumors.
    Murphy CE; McCormick KA; Shankaran V; Reddi DM; Swanson PE; Upton MP; Papanicolau-Sengos A; Khor S; Westerhoff M
    Pancreas; 2017; 46(10):1359-1365. PubMed ID: 29040195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD133 expression in well-differentiated pancreatic neuroendocrine tumors: a potential predictor of progressive clinical courses.
    Sakai Y; Hong SM; An S; Kim JY; Corbeil D; Karbanová J; Otani K; Fujikura K; Song KB; Kim SC; Akita M; Nanno Y; Toyama H; Fukumoto T; Ku Y; Hirose T; Itoh T; Zen Y
    Hum Pathol; 2017 Mar; 61():148-157. PubMed ID: 27864124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of methods for proliferative index analysis for grading pancreatic well-differentiated neuroendocrine tumors.
    Goodell PP; Krasinskas AM; Davison JM; Hartman DJ
    Am J Clin Pathol; 2012 Apr; 137(4):576-82. PubMed ID: 22431534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification.
    Yang Z; Tang LH; Klimstra DS
    Am J Surg Pathol; 2011 Jun; 35(6):853-60. PubMed ID: 21566513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma.
    Xu B; Fuchs TL; Ahmadi S; Alghamdi M; Alzumaili B; Bani MA; Baudin E; Chou A; De Leo A; Fagin JA; Ganly I; Glover A; Hartl D; Kanaan C; Khneisser P; Najdawi F; Nigam A; Papachristos A; Repaci A; Spanheimer PM; Solaroli E; Untch BR; Barletta JA; Tallini G; Al Ghuzlan A; Gill AJ; Ghossein RA
    J Clin Oncol; 2022 Jan; 40(1):96-104. PubMed ID: 34731032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival and prognostic factors in well-differentiated pancreatic neuroendocrine tumors.
    Boyar Cetinkaya R; Vatn M; Aabakken L; Bergestuen DS; Thiis-Evensen E
    Scand J Gastroenterol; 2014 Jun; 49(6):734-41. PubMed ID: 24679166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors.
    Villani V; Mahadevan KK; Ligorio M; Fernández-Del Castillo C; Ting DT; Sabbatino F; Zhang I; Vangel M; Ferrone S; Warshaw AL; Lillemoe KD; Wargo J; Deshpande V; Ferrone CR
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):609-617. PubMed ID: 27020585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of different anti-Ki67 antibody clones and hot-spot sizes for assessing proliferative index and grading in pancreatic neuroendocrine tumours using manual and image analysis.
    Owens R; Gilmore E; Bingham V; Cardwell C; McBride H; McQuaid S; Humphries M; Kelly P
    Histopathology; 2020 Oct; 77(4):646-658. PubMed ID: 32617996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.